antiantibody
bezlotoxumab
talizumab
immunoprotective
drozitumab
intrabody
elotuzumab
tucotuzumab
sonepcizumab
conatumumab
antimonoclonal
robatumumab
durvalumab
siltuximab
mapatumumab
idiospecific
adebrelimab
antipolyvalent
ocrelizumab
atezolizumab
etesevimab
teplizumab
immunoprotection
heteroclitic
polyvalent
dorlixizumab
ozoralizumab
olendalizumab
afasevikumab
antinucleoside
adjuvant
antiplasma
polyantibody
panitumumab
immunogen
microlymphocytotoxicity
chromobody
immunoadsorbent
pancytokeratin
monospecific
agonistic monoclonal antibody
teclistamab
matuzumab
bispecific
antigenomic
antiantitoxin
lintuzumab
presentation
agglutin
belimumab